CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around
the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs,
and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing
medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy
and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
Immune Forward-Looking Statement
press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other
than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s
strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,”
“might,” “will,” “should,” “expects,” “plans,” “anticipates,”
“believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook”
or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current
expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business
decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described
under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review
and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.
Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update
them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking
statements are qualified in their entirety by this cautionary statement.
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act
of 1995) about the benefits of the license and collaboration with AC Immune, and reflects Lilly's current beliefs. However, as
with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization.
Among other things, there can be no guarantee that Lilly will realize the expected benefits of the license and collaboration,
or that the license and collaboration will yield a commercially successful
For a further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations,
please see Lilly's most recent Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no
duty to update forward-looking statements.
# # #